Clinical Trial Update: Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating DZD6008, an oral EGFR inhibitor from Dizal Pharmaceuticals, in patients with advanced non-small cell lung cancer harboring EGFR mutat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DZD6008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Nonsmall-cell Lung Cancer | Phase 1 | Status: RECRUITING